Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

MedComm

Showing results (1041-1050 of 1,389) with videos related to

Pageof 139
Sort By:
Medcomm|September 3, 2025
Programmed Cell Death in CancerYuang Wei, William Hankey, Dongliang Xu, et al.
Medcomm|September 2, 2025
Epithelial-Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical ImplicationsDhasarathdev Srinivasan, Ranjith Balakrishnan, Ankush Chauhan, et al.
Medcomm|September 2, 2025
Targeting the Hippo/YAP Pathway: A Promising Approach for Cancer Therapy and BeyondRajni Bala, Reecha Madaan, Onkar Bedi, et al.
Medcomm|May 26, 2022
Deletion of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma progression by activating glucose metabolism and YAP signalingYang Li, Shuting Yang, Yang Liu, et al.
Medcomm|May 23, 2022
Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunitiesZhao Huang, Zhe Zhang, Chengwei Zhou, et al.
Medcomm|July 7, 2021
Risk factors associated with deep vein thrombosis in COVID-19 patientsBin Wang, Li Zhang, Shanye Yin, et al.
Medcomm|November 12, 2021
Metabolism in tumor microenvironment: Implications for cancer immunotherapyRongchen Shi, Yi-Quan Tang, Hongming Miao
Medcomm|November 12, 2021
Intermedin promotes vessel fusion by inducing VE-cadherin accumulation at potential fusion sites and to achieve a dynamic balance between VE-cadherin-complex dissociation/reconstitutionLingmiao Kong, Fei Xiao, Lijun Wang, et al.
Medcomm|November 12, 2021
A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironmentChenjing Zhu, Huashan Shi, Min Wu, et al.
Medcomm|November 12, 2021
Mitochondria as a target in cancer treatmentYu'e Liu, Yufeng Shi
Pageof 139

Showing results (1041-1050 of 1,389) with videos related to

Sort By:
Pageof 139
Medcomm|September 3, 2025
Programmed Cell Death in CancerYuang Wei, William Hankey, Dongliang Xu, et al.
Medcomm|September 2, 2025
Epithelial-Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical ImplicationsDhasarathdev Srinivasan, Ranjith Balakrishnan, Ankush Chauhan, et al.
Medcomm|September 2, 2025
Targeting the Hippo/YAP Pathway: A Promising Approach for Cancer Therapy and BeyondRajni Bala, Reecha Madaan, Onkar Bedi, et al.
Medcomm|May 26, 2022
Deletion of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma progression by activating glucose metabolism and YAP signalingYang Li, Shuting Yang, Yang Liu, et al.
Medcomm|May 23, 2022
Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunitiesZhao Huang, Zhe Zhang, Chengwei Zhou, et al.
Medcomm|July 7, 2021
Risk factors associated with deep vein thrombosis in COVID-19 patientsBin Wang, Li Zhang, Shanye Yin, et al.
Medcomm|November 12, 2021
Metabolism in tumor microenvironment: Implications for cancer immunotherapyRongchen Shi, Yi-Quan Tang, Hongming Miao
Medcomm|November 12, 2021
Intermedin promotes vessel fusion by inducing VE-cadherin accumulation at potential fusion sites and to achieve a dynamic balance between VE-cadherin-complex dissociation/reconstitutionLingmiao Kong, Fei Xiao, Lijun Wang, et al.
Medcomm|November 12, 2021
A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironmentChenjing Zhu, Huashan Shi, Min Wu, et al.
Medcomm|November 12, 2021
Mitochondria as a target in cancer treatmentYu'e Liu, Yufeng Shi
Pageof 139